Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Authors

Vivian Chua, Thomas Jefferson UniversityFollow
Dominic Lapadula, Thomas Jefferson UniversityFollow
Clinita Randolph, Thomas Jefferson UniversityFollow
Jeffrey L. Benovic, Thomas Jefferson UniversityFollow
Philip B. Wedegaertner, Thomas Jefferson UniversityFollow
Andrew E. Aplin, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

5-1-2017

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Molecular Cancer Research, Volume 15, Issue 5, May 2017, Pages 501-506.

The published version is available at https://doi.org/10.1158/1541-7786.MCR-17-0007 Copyright © American Association for Cancer Research Inc.

Abstract

Uveal melanoma is the most common primary intraocular malignant tumor in adults and arises from the transformation of melanocytes in the uveal tract. Even after treatment of the primary tumor, up to 50% of patients succumb to metastatic disease. The liver is the predominant organ of metastasis. There is an important need to provide effective treatment options for advanced stage uveal melanoma. To provide the preclinical basis for new treatments, it is important to understand the molecular underpinnings of the disease. Recent genomic studies have shown that mutations within components of G protein-coupled receptor (GPCR) signaling are early events associated with approximately 98% of uveal melanomas.

Recommended Citation

Chua, Vivian; Lapadula, Dominic; Randolph, Clinita; Benovic, Jeffrey L.; Wedegaertner, Philip B.; and Aplin, Andrew E., "Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma." (2017). Department of Biochemistry and Molecular Biology Faculty Papers. Paper 134.
https://jdc.jefferson.edu/bmpfp/134

PubMed ID

28223438

Language

English